Maravai LifeSciences Holdings Past Earnings Performance
Past criteria checks 0/6
Maravai LifeSciences Holdings's earnings have been declining at an average annual rate of -18.3%, while the Life Sciences industry saw earnings growing at 19.1% annually. Revenues have been declining at an average rate of 14.3% per year.
Key information
-18.3%
Earnings growth rate
-48.3%
EPS growth rate
Life Sciences Industry Growth | 26.8% |
Revenue growth rate | -14.3% |
Return on equity | -20.5% |
Net Margin | -47.8% |
Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Maravai LifeSciences Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Mar 24 | 274 | -131 | 150 | 18 |
31 Dec 23 | 289 | -119 | 147 | 17 |
30 Sep 23 | 420 | 25 | 146 | 22 |
30 Jun 23 | 544 | 75 | 141 | 22 |
31 Mar 23 | 718 | 153 | 134 | 21 |
31 Dec 22 | 883 | 220 | 126 | 18 |
30 Sep 22 | 907 | 238 | 115 | 16 |
30 Jun 22 | 920 | 248 | 109 | 15 |
31 Mar 22 | 895 | 226 | 105 | 15 |
31 Dec 21 | 799 | 182 | 100 | 15 |
30 Sep 21 | 669 | 150 | 116 | 8 |
30 Jun 21 | 552 | 127 | 108 | 8 |
31 Mar 21 | 381 | 78 | 101 | 5 |
31 Dec 20 | 284 | 77 | 94 | 6 |
31 Dec 19 | 143 | -8 | 48 | 4 |
31 Dec 18 | 124 | -18 | 41 | 4 |
Quality Earnings: MAR is currently unprofitable.
Growing Profit Margin: MAR is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: MAR is unprofitable, and losses have increased over the past 5 years at a rate of 18.3% per year.
Accelerating Growth: Unable to compare MAR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MAR is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (-1.7%).
Return on Equity
High ROE: MAR has a negative Return on Equity (-20.54%), as it is currently unprofitable.